Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples